Clinical outcomes of patients with advanced NSCLC with different EGFR exon 19 deletion subtypes treated with first-line tyrosine kinase inhibitors

被引：0
|
作者：
Gu, Yangchun
Yu, JinYu
Hu, Haifeng
Zhang, Hua
Cao, Baoshan
Liang, Li
机构：
[1] Peking Univ Third Hosp, Beijing, Peoples R China
[2] Yanan City Hosp Tradit Chinese Med, Yanan, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21034
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Audit of outcomes of NSCLC treated with first line EGFR inhibitors in a district general hospital
    Chennupati, J.
    De Winton, E.
    Frim, O.
    Sephton, M.
    Cox, R. A.
    LUNG CANCER, 2018, 115 : S33 - S33
  • [42] CLINICAL OUTCOMES AFTER FIRST-LINE EGFR-TKI FOR PATIENTS WITH NSCLC, EGFR MUTATION, AND POOR PERFORMANCE STATUS
    Nagamata, Makoto
    Okuma, Yusuke
    Sunami, Kuniko
    Hosomi, Yukio
    Okamura, Tatsuru
    ANNALS OF ONCOLOGY, 2014, 25
  • [43] Effect of ABO blood type on the outcomes of patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors
    Omae, Kenji
    Fukuma, Shingo
    Ikenoue, Tatsuyoshi
    Kondo, Tsunenori
    Takagi, Toshio
    Ishihara, Hiroki
    Tanabe, Kazunari
    Fukuhara, Shunichi
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2017, 35 (09) : 540.e7 - 540.e12
  • [44] Effect of ABO blood type on the outcomes of metastatic renal cell carcinoma patients treated with first-line tyrosine kinase inhibitors
    Omae, Kenji
    Fukuma, Shingo
    Ikenoue, Tatsuyoshi
    Kondo, Tsunenori
    Takagi, Toshio
    Ishihara, Hiroki
    Tanabe, Kazunari
    Fukuhara, Shunichi
    INTERNATIONAL JOURNAL OF UROLOGY, 2018, 25 : 391 - 391
  • [45] Clinical Outcomes After First-line EGFR Inhibitor Treatment for Patients with NSCLC, EGFR Mutation, and Poor Performance Status
    Okuma, Yusuke
    Hosomi, Yukio
    Nagamata, Makoto
    Yamada, Yuko
    Sekihara, Kuniko
    Kato, Kan
    Hishima, Tsunekazu
    Okamura, Tatsuru
    ANTICANCER RESEARCH, 2013, 33 (11) : 5057 - 5064
  • [46] The clinical outcomes of different first-line treatment strategies in advanced non-small cell lung cancer patients with EGFR exon 20 insertion mutation
    Ou, Wei-Fan
    Huang, Yen-Hsiang
    Hsu, Kuo-Hsuan
    Tseng, Jeng-Sen
    Lee, Po-Hsin
    Yang, Tsung-Ying
    RESPIROLOGY, 2023, 28 : 100 - 101
  • [47] Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with NSCLC Harboring EGFR Exon 19 Insertions: A Report from the LC-SCRUM-Asia
    Uehara, Y.
    Izumi, H.
    Kobayashi, I. S.
    Matsumoto, S.
    Hosomi, Y.
    Okuno, T.
    Sugisaka, J.
    Takase, N.
    Taima, K.
    Sasaki, S.
    Teranishi, S.
    Miyamoto, S.
    Mori, M.
    Nakashima, C.
    Asano, S.
    Zenke, Y.
    Yoh, K.
    Costa, D. B.
    Kobayashi, S. S.
    Goto, K.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S191 - S192
  • [48] COST OF MANAGING BRAIN METASTASES IN PATIENTS WITH ALK-POSITIVE ADVANCED NSCLC WITH FIRST-LINE ALK TYROSINE KINASE INHIBITORS (TKIS) IN CHINA
    Hu, B.
    Xue, J.
    Siman, L.
    Duan, J.
    Luan, L.
    Le, H.
    Dong, P.
    Li, H.
    VALUE IN HEALTH, 2024, 27 (12) : S101 - S101
  • [49] Baseline Tumor Size and Survival Outcomes among Patients with Advanced NSCLC treated with First-Line Immunotherapy
    Uehara, Y.
    Hakozaki, T.
    Kitadai, R.
    Hosomi, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S392 - S392
  • [50] EGFR mutation types and abundance were associated with the overall survival of advanced lung adenocarcinoma patients receiving first-line tyrosine kinase inhibitors
    Liu, Yang
    Wang, Hongyan
    Yang, Sen
    Yang, Yuanyuan
    Wu, Yufeng
    He, Zhen
    Ma, Shuxiang
    Mo, Yuqing
    Chen, Haiyang
    Wang, Qiming
    Ge, Hong
    JOURNAL OF THORACIC DISEASE, 2022, 14 (06) : 2254 - 2267
12345